Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

574 ARTÍCULOS , VIENDO DEL 451 AL 465

Alzheimer Disease Clinical Trials Targeting Amyloid: Lessons Learned From Success in Mice and Failure in Humans

Reiss AB, Montufar N, DeLeon J, Pinkhasov A, Gomolin IH, Glass AD, Arain HA, Stecker MM.

Neurologist. 2021 Mar 4;26(2):52-61. doi: 10.1097/NRL.0000000000000320.

Alzheimer's disease and its treatment by different approaches: A review

Srivastava S, Ahmad R, Khare SK.

Eur J Med Chem. 2021 Apr 15;216:113320. doi: 10.1016/j.ejmech.2021.113320. Epub 2021 Feb 23.

Therapy for Alzheimer's disease: Missing targets and functional markers?

Stoiljkovic M, Horvath TL, Hajós M.

Ageing Res Rev. 2021 Jul;68:101318. doi: 10.1016/j.arr.2021.101318. Epub 2021 Mar 9.

Hypothesis: Intravenous administration of mesenchymal stem cells is effective in the treatment of Alzheimer's disease

Shigematsu K, Takeda T, Komori N, Tahara K, Yamagishi H.

Med Hypotheses. 2021 May;150:110572. doi: 10.1016/j.mehy.2021.110572. Epub 2021 Mar 23.

Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer's Disease Platform

Karelina T, Lerner S, Stepanov A, Meerson M, Demin O.

CPT Pharmacometrics Syst Pharmacol. 2021 Jun;10(6):543-550. doi: 10.1002/psp4.12628. Epub 2021 May 2.

Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges

Cano A, Turowski P, Ettcheto M, Duskey JT, Tosi G, Sánchez-López E, García ML, Camins A, Souto EB, Ruiz A, Marquié M, Boada M.

J Nanobiotechnology. 2021 Apr 29;19(1):122. doi: 10.1186/s12951-021-00864-x.

BACE1: from biomarker to Alzheimer's disease therapeutical target

Cervellati C, Valacchi G, Zuliani G.

Aging (Albany NY). 2021 May 11;13(9):12299-12300. doi: 10.18632/aging.203064. Epub 2021 May 11.

ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease

Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, Ropele S, Fialova L, Kramberger M, Paulenka-Ivanovova N, Smisek M, Hanes J, Stevens E, Kovac A, Sutovsky S, Parrak V, Koson P, Prcina M, Galba J, Cente M, Hromadka T, Filipcik P, Piestansky J, Samcova M, Prenn-Gologranc C, Sivak R, Froelich L, Fresser M, Rakusa M, Harrison J, Hort J, Otto M, Tosun D, Ondrus M, Winblad B, Novak M, Zilka N.

Nat Aging. 2021 Jun;1(6):521-534. doi: 10.1038/s43587-021-00070-2. Epub 2021 Jun 14.

Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment

Nakai T, Yamada K, Mizoguchi H.

Int J Mol Sci. 2021 May 24;22(11):5549. doi: 10.3390/ijms22115549.

Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease

Kellar D, Lockhart SN, Aisen P, Raman R, Rissman RA, Brewer J, Craft S.

J Prev Alzheimers Dis. 2021;8(3):240-248. doi: 10.14283/jpad.2021.14.

Lithium: A therapeutic option in Alzheimer's disease and its prodromal stages?

Haussmann R, Noppes F, Brandt MD, Bauer M, Donix M.

Neurosci Lett. 2021 Aug 24;760:136044. doi: 10.1016/j.neulet.2021.136044. Epub 2021 Jun 10.

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease

Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, Cruchaga C, Goate AA, Perrin RJ, Xiong C, Li Y, Morris JC, Snider BJ, Mummery C, Surti GM, Hannequin D, Wallon D, Berman SB, Lah JJ, Jimenez-Velazquez IZ, Roberson ED, van Dyck CH, Honig LS, Sánchez-Valle R, Brooks WS, Gauthier S, Galasko DR, Masters CL, Brosch JR, Hsiung GR, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Jack CR Jr, Koeppe R, Snyder PJ, Aisen PS, Thomas RG, Berry SM, Wendelberger BA, Andersen SW, Holdridge KC, Mintun MA, Yaari R, Sims JR, Baudler M, Delmar P, Doody RS, Fontoura P, Giacobino C, Kerchner GA, Bateman RJ; Dominantly Inherited Alzheimer Network–Trials Unit.

Nat Med. 2021 Jul;27(7):1187-1196. doi: 10.1038/s41591-021-01369-8. Epub 2021 Jun 21.

Recent advances on drug development and emerging therapeutic agents for Alzheimer's disease

Athar T, Al Balushi K, Khan SA.

Mol Biol Rep. 2021 Jul;48(7):5629-5645. doi: 10.1007/s11033-021-06512-9. Epub 2021 Jun 28.

Therapeutic potential of astaxanthin and superoxide dismutase in Alzheimer's disease

Balendra V, Singh SK.

Open Biol. 2021 Jun;11(6):210013. doi: 10.1098/rsob.210013. Epub 2021 Jun 30.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias